Hologic to Divest Stake in Blood Screening Business to Grifols for $1.85B

Dec 14, 2016

|

NEW YORK (GenomeWeb) – Hologic announced after the close of the market on Wednesday that it will sell its share of a blood screening business to Grifols, its commercial partner, in a deal worth $1.85 billion in cash.

The boards of directors of both companies have approved the deal.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Hologic to Divest Stake in Blood Screening Business to Grifols for $1.85B

To read the full story....

Breaking News

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Siemens Healthineers Q1 Diagnostics Revenues Rise 17 Percent on Pandemic-Related Demand

Abbott Panbio SARS-CoV-2 Rapid Antigen Test Nabs CE Mark for Asymptomatic Screening, Self-Collection

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Infectious Disease Test Firm Talis Biomedical Files for IPO

Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

NASA Looking to Spin Out Breath Analysis Platform for Use in Diagnostics Applications

Sponsorships